Introduction
Tissue-type plasminogen activator (t-PA) is a serine protease, catalyzing the initial step in the fibrinolytic process. Intravenously administered t-PA is rapidly cleared from the circulation by the liver. Two distinct clearance mechanisms, which are mediated by the low density lipoprotein receptorrelated protein (LRP) on liver parenchymal cells and by the mannose receptor on liver endothelial cells, have been described. Using competitors and inhibitors of the receptors, we investigated the role of LRP and carbohydrate receptors in t-PA clearance in vivo. To inhibit LRP, the 39-kD protein, which is a potent inhibitor of LRP activity, was overexpressed in the liver of mice using an adenoviral gene transfer technique. Expression of the 39-kD protein resulted in a sustained plasma concentration and an increase in the plasma half-life of '"I-t-PA from less than 1 min to [4] [5] min. Blockade of the mannose receptor by intravenous administration of ovalbumin also prolonged the plasma halflife of '25I-t-PA to 3-4 min. The same degree of inhibition of t-PA clearance was also observed after administration of an inhibitor of the fucose receptor, fucosyl-BSA. However, under the conditions established for the complete blockade of the mannose receptor, no additional inhibition of t-PA clearance was observed using fucosyl-BSA, suggesting little or no role for the fucose receptor in the clearance of t-PA. Furthermore, a dramatic increase of the plasma half-life of '"I-t-PA (> 20 min) was observed in mice overexpressing 39-kD protein and administered ovalbumintfucosyl-BSA. Our Adenovirus purification. Recombinant adenovirus containing the full-length rat 39-kD protein cDNA (AdCMV-39-kD) or the Escherichia coli /3-galactosidase gene (AdCMV-,8-Gal) were prepared as described previously (13) . Virus particle number was assessed from the OD2w. of the purified virus preparation (1 OD2w = 5 x 10" virus particles/ml). Virus viability was determined by infecting 293 cells at limiting dilutions and evaluating /3-galactosidase production 18 h later.
The titer was 100 virus particles per plaque forming unit.
Purification of the 39-kD protein. Purification of the 39-kD protein after expression in Escherichia coli was carried out as described previously (10) .
Antibody production. Rabbit polyclonal antibodies against the full-length 39-kD protein were prepared as described previously (11).
In vivo viral delivery. Recombinant adenovirus containing either the AdCMV-39-kD or AdCMV-,/-Gal was injected intravenously via tail vein into 12-16-wk old BALB/c mice. Plasma 39-kD protein was detected after day 2, peaked at days 4-6, and thereafter declined (see Results). Therefore, all clearance studies were performed on day 5 after virus injection. Various viral particle doses were examined as described in the text. Optimal expression was achieved after administration of 4 x 10' particles (4 x I09 plaque forming units) of either AdCMV-39-kD or AdCMV-/3-Gal.
In vivo plasma clearance. 12-16-wk old BALB/c mice (weighing 20-25 g) were anesthetized with sodium pentobarbital (1 mg/20 g body wt mouse) during the course of the experiment. The indicated radiolabeled protein (6.4 pmol of t-PA, [6.0 X 106 cpm/,jg], 13.9 pmol of a2M*, [1.3 X 107 cpmlsg]) in sterile saline (total vol 100 il) was injected into a tail vein over 30 s. In studies where glycosylated albumins were administered, these competitors were injected 1 min before administration of the radiolabeled t-PA. At the indicated times, 40-50 Itl of blood was collected by periorbital bleeding. '"'I-radiolabeled protein in the plasma samples was determined as described previously (10) . Generally, at least three mice were independently evaluated for each clearance study, with nearly identical clearance curves within each experimental condition.
Immunoblotting. Plasma from uninjected mice, or from mice after administration of 2-6 x 10" particles of AdCMV-,B-Gal or AdCMV-39-kD, was obtained 5 d after virus administration. Samples (3 sl) were electrophoresed on 10% SDS-polyacrylamide gel and transferred electrophoretically to nitrocellulose for immunoblot analysis using polyclonal affinity-purified anti-39-kD IgG.
Pharmacokinetic analysis. Plasma l"I-t-PA concentrations during the 20-min clearance studies were analyzed via the pharmacokinetic clearance formula:
where the coefficients A and exponential values B were derived via the "'cstrip" program using a two-exponential fit (14, 15) , herein a phase tl/2 = 0.693/B2, /3 phase tl,2 = 0.693/Bl.
Results
Expression of adenoviral-mediated 39-kD protein in vivo. To evaluate the efficiency of adenoviral gene transduction in vivo, we performed semiquantitative protein immunoblot analyses. 4
x 10" viral particles (2x) (-4 X analyzed (lanes 6-9). Plasma clearance of '"I-a2M* was determined for duplicate samples.
shown expression in a majority of hepatocytes under these conditions (16). 5 d after administration of the recombinant virus, plasma was obtained and subjected to immunoblotting ( quantitative immunoblot analysis and were 20-50 ,g/ml, 50-400 jHg/ml, and 100-600 jsg/ml, respectively (data not shown).
Upon pathological review, no gross or microscopic morphological differences in the liver (including no evidence l25sIt4pA clearance in the presence of various competitors. The plasma clearance of 1251-t-PA after intravenous administration of 6.4 pmol of '"I-t-PA in mice is shown in Fig. 2 (Fig.   2 , A and B, no injection). The initial plasma half-life of '251-t-PA was 30 s-i min with < 10% of the administered dose remaining in the circulation at 10 min (a phase t1/2 -0.3 min, /3 phase t1/2 -11 min, Table I ). This clearance curve is similar to that of the plasma clearance of 1251-t-PA in rats (6) .
To confirm that no adverse effect on the clearance of 1251I t-PA was induced by the viral infection, clearance studies of 1251-t-PA were performed in mice after administration of AdCMV-/P-Gal. As seen in Fig. 3 A, the clearance of '251-t-PA in AdCMV-,/-Gal-infected mice was essentially the same as that of noninfected mice (a phase t1,2 -0.6 minm, phase t1,2 -9 min, Table I ). To assess the functional effect of the 39-kD protein overexpressed via the adenoviral system, we determined the clearance of 125I-t-PA in AdCMV-39-kD-infected mice. Previously, we have demonstrated that the purified 39-kD protein inhibited 1251_ t-PA binding to MHIC1 cells (4) and that intravenous administration of the purified 39-kD protein to rats prolonged the plasma half-life of '251-t-PA in vivo (10) . In the present studies, we used an adenoviral vector carrying the 39-kD protein cDNA to generate recombinant protein in vivo. 2 x 1011 (1 X), or 4 X 1011 (2x), or 6 x 1011 (3x) particles of AdCMV-39-kD were intravenously administered to mice via tail vein. 5 d after administration, plasma clearance studies of 1251-t-PA were performed. As seen in Fig. 3 B, AdCMV-39-kD-infected mice.
cleared 125I-t-PA more slowly with plasma half-lives of -2 min (lx), 3.5 min (2x), and 4 min (3X) for the respective doses. Although the effect of AdCMV-39-kDa on the clearance of 125I-t-PA was dose dependent, 3x the AdCMV-39-kDa dose (i.e., 6 x 1011 particles) resulted in near saturation of t-PA clearance. Since 125I-a2M * is an LRP-specific ligand, and since 1251-t-PA is cleared not only by LRP but also by other (carbohydrate) receptor(s), the apparent discrepancy in the effect on ligand clearance between 125I-a2M* and 125I-t-PA is likely explained by the participation of other clearance mechanism(s).
To investigate the possible involvement of carbohydrate receptors in the clearance of '25I-t-PA, we next performed clear- I ). These results are in agreement with previous observations (6) . The 125I-t-PA clearance profile in mice administered 10 mg of ovalbumin was identical to that seen after the administration of 5 mg of ovalbumin (Fig. 2 A) Fig. 2, A and B, for maximal dosage of ovalbumin or fucosyl-BSA when administered independently (data not shown).
To examine whether LRP and the mannose receptor were able to function independently as clearance receptors in vivo, we next combined the administration of the competitors with these two receptor systems. As seen in Fig. 3 C, preadministration of ovalbumin (5 mg) to AdCMV-39-kD-infected mice dramatically prolonged the plasma half-life of 125I-t-PA compared with that observed with either competitor alone ( Fig. 2 A and Fig. 3 B) . The average half-life of 1251-t-PA in these mice was >> remained similar to those injected with ovalbumin alone, while the half-life for the , phase (t112 > 200 min) increased dramatically. Furthermore, the addition of fucosyl-BSA did not result in any further effect on '"I-t-PA clearance (Fig. 3 B) . Although markedly diminished in the presence of LRP and mannose receptor competitors, '25I-t-PA clearance was still detectable. This could be due either to incomplete inhibition of these two receptor systems or to the existence of minor unknown clearance mechanism(s) for t-PA.
Discussion
The present observations demonstrate that (a) inactivation of LRP in vivo by gene transfer of a receptor antagonist inhibits hepatic clearance of '"I-a2M *; (b) inactivation of LRP by the 39-kD protein prolongs the plasma half-life of '"I-t-PA; (c) blockade of the mannose receptor by administration of ovalbumin also prolongs the plasma half-life of "'I-t-PA; (d) under the conditions established for the complete blockade of mannose receptor, no additional inhibition on t-PA clearance is observed when using an inhibitor of the fucose receptor; and (e) a dramatic increase of the plasma half-life of t-PA (> 30-fold) is observed in the mice overexpressing the 39-kD protein and coadministered a competitor of the mannose receptor. These results indicate that both LRP and the mannose receptor are responsible for t-PA clearance in vivo.
t-PA plays a central role in the fibrinolytic process by converting plasminogen to plasmin. This role for t-PA has been applied clinically for clot dissolution, especially in patients suffering from acute myocardial infarction (1). However, one major drawback to the clinical use of t-PA is its rapid clearance from the blood in vivo. Exogenously administered t-PA is cleared from the circulation via receptor-mediated endocytosis. So far, two receptor systems have been reported to be responsible for the clearance of t-PA in vivo: (a) LRP is a hepatic receptor for both free t-PA and t-PA complexed with plasminogen activator inhibitor type-i (4, 18, 19) ; (b) the mannose receptor, present primarily on liver endothelial cells, recognizes mannose-rich oligosaccharides (17) . Based on subfractionation studies of the liver, parenchymal cells are responsible for > 50% of the interaction of t-PA with the liver (6). Thus, LRP on the parenchymal cells is responsible for the majority of hepatic t-PA clearance. We previously demonstrated that the 39-kD protein, a specific inhibitor of LRP, blocked the binding and uptake of t-PA (4, 18) , as well as t-PA: plasminogen activator inhibitor type-i complexes (19) . Recently, we also demonstrated that intravenous administration of purified recombinant 39-kD protein prolonged the plasma half-life of t-PA in vivo (10) (20) . Within the carbohydrate receptor family, the mannose receptor on rat liver endothelial cells has been shown to be responsible in part for the rapid clearance of t-PA (21) . The present findings (Fig. 2) are consistent with these earlier observations.
Importantly, we demonstrate a dramatic increase of the plasma half-life of t-PA (from 0.5 to min in control to > 20 min) in mice overexpressing the 39-kD protein and administered ovalbumin, an inhibitor of the mannose receptor (Fig. 3  C) . These results demonstrate that two independent receptor systems, LRP and the mannose receptor, are involved in the hepatic clearance of t-PA. Consistent with these observations, hepatic cell fractionation studies by Kuiper et al. (6) after administration of '"I-t-PA in vivo have demonstrated that parenchymal cells account for -55% of t-PA uptake, whereas endothelial cells account for an additional -40%. Furthermore, preadministration of ovalbumin virtually eliminated endothelial cell t-PA uptake, without substantial effect on t-PA uptake by parenchymal cells (6) . This is consistent with the known localization of the mannose receptor to endothelial cells (6) and LRP to parenchymal cells (22) . The physiological significance of the presence of two independent hepatic t-PA clearance mechanisms is not clear at present. However, the differential cellular distribution between the mannose receptor and LRP suggests that LRP may be responsible for t-PA clearance mainly in the liver parenchyma, whereas the mannose receptor on macrophages and endothelial cells may regulate the levels of free t-PA in a more local process, such as inflammation.
In addition to N-glycosylation sites, an 0-linked a-fucose moiety has been recently identified on threonine-61 within the EGF domain of t-PA. Fucosylated threonine is also found in rat and mouse t-PA. Similar fucosylation is also observed in prourokinase, a fibrinolytic protein of similar structure and function to t-PA (23) . The functional role of fucosylation at threonine-61 is unknown (24 (25) , were responsible for < 5% of the t-PA cleared via the liver (6), in further support of our conclusion.
In the presence of competitors for LRP and the mannose receptor, 1"I-t-PA continued to be cleared, but at a very slow rate. This may be due either to incomplete blockade of the two receptor systems or to the existence of a minor unknown clearance mechanism(s) for t-PA. Nonetheless, the present observations cleary demonstrate that LRP and the mannose receptor are responsible for the vast majority of lz5I-t-PA clearance in vivo.
